A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update.

被引：0
|
作者：
van Oosterom, A
Reichardt, P
Blay, JY
Dumez, H
Fletcher, J
Debiec-Rychter, M
Shand, N
Drimitrijevic, S
Yap, A
Demetri, G
机构：
[1] UZ Gasthuisberg, Louvain, Belgium
[2] Charite, Berlin, Germany
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Novartis Pharm AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：824S / 824S
页数：1
相关论文
共 50 条
  • [1] Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM.
    Van Oosterom, AT
    Dumez, H
    Desai, J
    Stroobants, S
    Van den Abbeele, AD
    Clement, P
    Shand, N
    Kovarik, J
    Tsyrlova, A
    Demetri, GD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 195S - 195S
  • [2] A Phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM
    Reichardt, Peter
    Pink, Daniel
    Lindner, Tanja
    Heinrich, Michael C.
    Cohen, Pamela
    Wang, Yanfeng
    Tsyrlova, Anna
    Yap, Alan
    Dimitrijevic, Sasa
    Blanke, Charles D.
    ANNALS OF ONCOLOGY, 2004, 15 : 196 - 197
  • [3] A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM.
    Reichardt, P
    Pink, D
    Lindner, T
    Heinrich, MC
    Cohen, PS
    Wang, Y
    Yu, R
    Tsyrlova, A
    Dimitrijevic, S
    Blanke, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 196S - 196S
  • [4] A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study update
    Von Mehren, M.
    Reichardt, P.
    Casali, P. G.
    Blay, J.
    Debiec-Rychter, M.
    Dumez, H.
    Cheung, W.
    Feifel, B.
    Veronese, M.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST)
    D'Ambrosio, L.
    Ponzetti, A.
    Lista, P.
    Bombaci, S.
    Palesandro, E.
    Galizia, D.
    Aliberti, S.
    Allione, P.
    Manca, A.
    Gallo, S.
    Grignani, G.
    Aglietta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST).
    Bauer, Sebastian
    Hilger, Ralf A.
    Grabellus, Florian
    Nagarajah, James
    Hoiczyk, Mathias
    Reichardt, Annette
    Ahrens, Marit
    Pink, Daniel
    Muehlenberg, Thomas
    Scheulen, Max E.
    Schuler, Martin H.
    Reichardt, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Surgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy.
    Rutkowski, P
    Nowecki, Z
    Nyckowski, P
    Dziewirski, W
    Nasierowska-Guttmejer, A
    Grzesiakowska, U
    Michej, W
    Krawczyk, M
    Ruka, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 825S - 825S
  • [8] A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
    George, S.
    von Mehren, M.
    Heinrich, M. C.
    Wang, Q.
    Corless, C. L.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    Choy, E.
    Tap, W. D.
    Manola, J.
    Yap, J. T.
    Van den Abbeele, A. D.
    Solomon, S.
    Fletcher, J. A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning.
    Van den Abbeele, AD
    Badawi, RD
    Manola, J
    Morgan, JA
    Desai, J
    Kazanovicz, A
    St Armand, M
    Baum, C
    Demetri, GD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 198S - 198S
  • [10] Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST).
    Fletcher, JA
    Heinrich, MC
    Morgan, JA
    George, S
    Desai, J
    Scheu, K
    Fletcher, CDM
    Baum, C
    Demetri, GD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 818S - 818S
12345